User login
Key clinical point: Patients with advanced nonsquamous non–small-cell lung cancer (NSCLC) receiving first-line immune checkpoint inhibitors plus chemotherapy (ICI-chemo) have better overall survival (OS) than those receiving first-line bevacizumab plus chemotherapy (bev-chemo).
Major finding: Patients who received first-line ICI-chemo had a 21% longer OS than those who received bev-chemo (hazard ratio 0.79; 95% CI 0.66-0.94). There were no differences between the 2 groups in progression-free survival, objective response rate, and grade ≥3 treatment-related adverse events.
Study details: The data come from a network meta-analysis of 15 randomized controlled trials including 6561 patients with advanced nonsquamous NSCLC.
Disclosures: No funding information was available. The authors declared no conflicts of interest.
Source: Zhai J et al. First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials. Cancer Med. 2022 (Mar 22). Doi: 10.1002/cam4.4589
Key clinical point: Patients with advanced nonsquamous non–small-cell lung cancer (NSCLC) receiving first-line immune checkpoint inhibitors plus chemotherapy (ICI-chemo) have better overall survival (OS) than those receiving first-line bevacizumab plus chemotherapy (bev-chemo).
Major finding: Patients who received first-line ICI-chemo had a 21% longer OS than those who received bev-chemo (hazard ratio 0.79; 95% CI 0.66-0.94). There were no differences between the 2 groups in progression-free survival, objective response rate, and grade ≥3 treatment-related adverse events.
Study details: The data come from a network meta-analysis of 15 randomized controlled trials including 6561 patients with advanced nonsquamous NSCLC.
Disclosures: No funding information was available. The authors declared no conflicts of interest.
Source: Zhai J et al. First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials. Cancer Med. 2022 (Mar 22). Doi: 10.1002/cam4.4589
Key clinical point: Patients with advanced nonsquamous non–small-cell lung cancer (NSCLC) receiving first-line immune checkpoint inhibitors plus chemotherapy (ICI-chemo) have better overall survival (OS) than those receiving first-line bevacizumab plus chemotherapy (bev-chemo).
Major finding: Patients who received first-line ICI-chemo had a 21% longer OS than those who received bev-chemo (hazard ratio 0.79; 95% CI 0.66-0.94). There were no differences between the 2 groups in progression-free survival, objective response rate, and grade ≥3 treatment-related adverse events.
Study details: The data come from a network meta-analysis of 15 randomized controlled trials including 6561 patients with advanced nonsquamous NSCLC.
Disclosures: No funding information was available. The authors declared no conflicts of interest.
Source: Zhai J et al. First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials. Cancer Med. 2022 (Mar 22). Doi: 10.1002/cam4.4589